Project Grant R01NS143119
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$595K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This $195,896 Project Grant, awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to define the circuit connectivity between glioblastoma, a fatal brain cancer, and diverse neuronal populations in the mouse brain. The research aims to elucidate the role of cholinergic neuromodulatory inputs in regulating glioma progression, with the goal of...
This federal Project Grant award of $649,226 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to investigate mechanisms driving mesenchymal transition and therapeutic resistance in glioblastoma (GBM), a highly aggressive brain cancer. The research aims to dissect how tumors undergo this transition and acquire resistance to standard-of-care...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is focused on assessing the role of the SMARCA5 protein in glioblastoma, an incurable brain tumor. The $638,697 award to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University aims to determine how inhibiting SMARCA5 can force glioma stem cells to...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $687,279 to Beth Israel Deaconess Medical Center, Inc. (BIDMC) to conduct research on dissecting the orchestrated immune responses to glioblastoma within the native tissue microenvironment. The goal is to improve treatment outcomes by advancing the understanding of the diversity,...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to develop an encapsulated cell-based oncolytic virus therapy for brain tumors, specifically glioblastoma (GBM). The $420,251 award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, will fund the development and testing of mesenchymal stem...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $449,203 to Mayo Clinic Jacksonville (A Nonprofit Corporation) to investigate the mechanisms by which the subventricular zone (SVZ) neurogenic niche influences the malignancy of glioblastoma (GBM) brain tumors. The project aims to leverage novel cell-specific proteomic...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $717,802 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the University of Georgia Research Foundation, Inc. The grant supports research aimed at elucidating the cellular and molecular mechanisms underlying the development of a subtype of high-grade glioma brain tumors known as HGG-G34. Specifically, the research project seeks to unravel the...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $628,373 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on understanding how endogenous dendritic cells drive T cell activation and expansion in glioblastoma. The award period runs from August 1, 2025 to June 30,...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $443,354 to the University of Pittsburgh to conduct research on targeting the hexosamine biosynthetic pathway in pediatric brain tumors, specifically diffuse midline gliomas (DMG) harboring the H3K27M mutation. The research aims to investigate how this metabolic pathway supports tumor growth...